Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Expands By 62.7%

Entero Therapeutics, Inc. (NASDAQ:ENTO) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 152,900 shares, an increase of 62.7% from the October 31st total of 94,000 shares. Based on an average daily volume of 395,000 shares, the short-interest ratio is currently 0.4 days. Approximately 3.3% of the company’s shares are sold short.

Entero Therapeutics Trading Down 2.3 %

Shares of ENTO opened at $0.45 on Friday. Entero Therapeutics has a fifty-two week low of $0.19 and a fifty-two week high of $14.51. The company has a fifty day moving average of $0.51.

Entero Therapeutics (NASDAQ:ENTO) last issued its earnings results on Monday, October 21st. The company reported ($3.37) earnings per share for the quarter. Sell-side analysts forecast that Entero Therapeutics will post -1.13 earnings per share for the current fiscal year.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.